Mehmet Artaç
- Oncology top 5%
- Colorectal Cancer Treatments and Studies 17
- HER2/EGFR in Cancer Research 11
- Lung Cancer Research Studies 11
- Cancer Treatment and Pharmacology 10
- Cancer Diagnosis and Treatment 9
- Inflammatory Biomarkers in Disease Prognosis 9
- Pharmacology top 10%
- Geriatrics and Gerontology top 10%
-
- Lung Cancer Treatments and Mutations 17
- Gastric Cancer Management and Outcomes 9
- Co-authors
- Hakan BozcukMustafa ÖzdoğanBurhan SavaşMustafa SamurKadri AltundağMustafa KaraağaçHasan AltunbaşMustafa Yıldız
- Cited by
- OncologyPharmacologyCancer Research
- Journals
- Journal of Clinical Oncology (14 papers)SHILAP Revista de lepidopterología (5 papers)Cancer (1 paper)
- Partner nations
- TürkiyeUnited StatesSpain
In The Last Decade
Mehmet Artaç
106 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 108
- Oncology 528
- Pharmacology 69
- Cancer Research 112
- Geriatrics and Gerontology 29
- Pulmonary and Respiratory Medicine 202
Countries citing papers authored by Mehmet Artaç
This map shows the geographic impact of Mehmet Artaç's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehmet Artaç with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehmet Artaç more than expected).
Fields of papers citing papers by Mehmet Artaç
This network shows the impact of papers produced by Mehmet Artaç. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehmet Artaç. The network helps show where Mehmet Artaç may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mehmet Artaç, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 2 | |
| 10 | 2021 | 3 | |
| 11 | 2020 | 2 | |
| 12 | 2020 | 1 | |
| 13 | 2016 | 0 | |
| 14 | 2016 | 19 | |
| 15 | 2016 | 4 | |
| 16 | 2015 | 5 | |
| 17 | 2011 | 10 | |
| 18 | Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. | 2005 | 7 |
| 19 | 2004 | 33 | |
| 20 | A Novel Method of Reporting c-erbB-2 Overexpression: Correlation with Grade But Not with Other Prognostic Parameters in Breast Cancer* | 2003 | 2 |
About Mehmet Artaç
Mehmet Artaç is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology, having authored 127 papers that have together received 1.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (17 papers), HER2/EGFR in Cancer Research (11 papers), Lung Cancer Research Studies (11 papers), Cancer Treatment and Pharmacology (10 papers), Gastric Cancer Management and Outcomes (9 papers), Cancer Diagnosis and Treatment (9 papers) and Inflammatory Biomarkers in Disease Prognosis (9 papers). The work is most often cited by research in Oncology (528 citations), Pharmacology (69 citations) and Cancer Research (112 citations). Mehmet Artaç has collaborated with scholars based in Türkiye, United States and Spain. Frequent co-authors include Hakan Bozcuk, Mustafa Özdoğan, Burhan Savaş, Mustafa Samur, Kadri Altundağ, Mustafa Karaağaç, Hasan Altunbaş, Mustafa Yıldız, Murat Araz and Neslişah Rakıcıoğlu. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.